The NM_000023.4: c.197T>A variant in SGCA is a missense variant predicted to cause substitution of leucine by histidine at amino acid 66, p.(Leu66His). This variant has been detected in at least 10 individuals with limb-girdle muscular dystrophy, all of them were homozygous for the variant (1 pt; PMIDs: 33552634, 30564623, 31069529, 35416532) (PM3). At least one patient homozygous for this variant displayed progressive limb girdle muscle weakness and absent alpha-sarcoglycan protein expression, which is highly specific for SGCA-related LGMD (PP4_Strong; PMID: 35416532). The upper bound of the 95% confidence interval of the Grpmax variant allele frequency in gnomAD v4.1.1 is 0.0001724 (9/91072 South Asian alleles), which is higher than the LGMD VCEP threshold (<0.00009) for PM2_Supporting, and therefore does not meet this criterion. An in vitro assay in a heterologous cell system has demonstrated that this variant disrupts membrane localization of the sarcoglycan complex, indicating disruption of protein function (PS3_Moderate, Washington University internal data). The computational predictor REVEL also gives a score of 0.887, which is above the threshold of 0.7, evidence that correlates with impact to SGCA function (PP3). In summary, this variant meets the criteria to be classified as Likely Pathogenic for autosomal recessive limb girdle muscular dystrophy based on the ACMG/AMP criteria applied, as specified by the ClinGen LGMD VCEP (LGMD VCEP specifications version 2.0.0; 04/29/2026): PM3, PP4_Strong, PS3_Moderate, PP3.